|
Match
|
Document |
Document Title |
|
|
5800836 |
Pelletized pharmaceutical composition
A pelletized sustained release pharmaceutical composition including a core element including approximately 0.1 to 95% by weight, based on the total weight of the core element, of an active...
|
|
|
5776489 |
Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
A controlled release pharmaceutical composition in oral dosage unit form comprising a hard or a soft shell capsule containing a filling comprising a therapeutically effective number of active...
|
|
|
5776496 |
Ultrasmall porous particles for enhancing ultrasound back scatter
This invention relates to the preparation, composition and applications of suspensions of ultra-small, substantially non-aggregated, non-crystalline particles of predetermined uniform size which,...
|
|
|
5747017 |
Lip cosmetic
An improved lip cosmetic employing a coloring agent and a plasticizer in a volatile solvent includes a film-forming agent which preferably has as components an AMPHOMER and ethyl cellulose, as well...
|
|
|
5741522 |
Ultrasmall, non-aggregated porous particles of uniform size for entrapping gas bubbles within and methods
This invention relates to the preparation, composition and applications of suspensions of ultra-small, substantially non-aggregated, non-crystalline particles of predetermined uniform size which,...
|
|
|
5723151 |
Cellulose acetate phthalate enteric coating compositions
Provided are enteric coating compositions which utilize a low viscosity cellulose acetate phthalate polymer as a film former. The cellulose acetate phthalates have an inherent viscosity of about...
|
|
|
5709886 |
Effervescent microcapsules
Taste masked effervescent microcapsules are provided each microcapsule containing an effervescent admixture of sodium bicarbonate and citric acid microencapsulated with ethylcellulose, the...
|
|
|
5707646 |
Taste masking pharmaceutical composition
A composition for oral preparations, having a complex formed by dispersing or dissolving an unpleasantly tasting basic drug and a functional polymer compound in a substance having a low melting...
|
|
|
5705194 |
Pharmaceutical compositions containing polyalkylene block copolymers which gel at physiological temperature
There is disclosed a pharmaceutical composition which gels at physiological temperature. The composition is comprised of a block copolymer containing one or more polyoxyethylene blocks and one or...
|
|
|
5698220 |
Asymmetric membranes in delivery devices
A device for controlled release of an active substance through one or more asymmetric membranes by diffusion and/or osmotic pumping.
|
|
|
5688510 |
Process for producing stable medicinal composition, and pharmaceutical preparation
A process for producing a pharmaceutical composition is disclosed. In the process, 1 part by weight of a physiologically inert powdery additive, 0.001-1 part by weight of a macromolecular additive...
|
|
|
5683722 |
Orally-administered dosage form for animals, preparation method therefor and uses thereof
A dosage form for orally administering chemical or medicinal substances such as vitamins, trace elements, amino acids, nutritive substances, vaccines, etc., to domestic or wild animals, and a...
|
|
|
5681581 |
Controlled release pharmaceutical formulations of 3'-azido-3'-deoxythymidine and methods of use
This invention is directed to controlled release pharmaceutical formulations of 3'-azido-3'-deoxythymidine, also known as AZT or zidovudine and methods of use thereof. The controlled release...
|
|
|
5674529 |
Alkalinizing potassium salt controlled release preparations
Multiparticulate controlled release preparations incorporating an alkalinizing potassium salt, preferably potassium bicarbonate, as an active ingredient, which are suitable for forming...
|
|
|
5670171 |
Liquid-suspension controlled-release pharmaceutical composition
Disclosed is a liquid-suspension controlled-release enteric-coated pharmaceutical formulation for the administration of naproxen, comprising (a) microgranules of naproxen and an excipient; (b) four...
|
|
|
5670172 |
Pharmaceutical spheroid formulation
A controlled release composition including spheroid cores of diltiazem or a pharmaceutically acceptable salt thereof and optionally a spheronizing agent, the cores being coated with a controlled...
|
|
|
5648096 |
Process for the production of microcapsules
A method for the production of microcapsules embedded with pharmaceuticals, peptides, proteins, enzymes and vaccines, which uses biodegradable solvents, and microcapsules free of toxic residual...
|
|
|
5645858 |
Multilayered controlled release pharmaceutical dosage form
This invention is directed to a multilayered controlled release pharmaceutical dosage form. More particularly the dosage form is adapted for water soluble drugs and comprises a plurality of coated...
|
|
|
5643602 |
Oral composition for the treatment of inflammatory bowel disease
An oral pharmaceutical composition is described for targeted slow release in the treatment of inflammatory bowel diseases. Also described are pharmaceutical compositions for peroral treatment...
|
|
|
5639478 |
Method to stabilize a pharmaceutical composition and its production
The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R 1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy,...
|
|
|
5637322 |
Method for producing composition for solid medicine
In producing a composition for solid medicine, comprising, as an active ingredient, a potassium channel activator and a pharmaceutically acceptable water-insoluble cellulose polymer, a method for...
|
|
|
5635609 |
Particles prepared by transacylation reaction between an esterified polysaccharide and a polyamine, methods of preparation therefor and compositions containing same
Particles, preparation methods therefor, and compositions containing same. The particles include at least one esterified polysaccharide and at least one polyamine, as well as at least one gellable...
|
|
|
5622723 |
Procedure for encapsulating chlorpheniramine
An improvement in the process of coacervation of chlorpheniramine maleate is provided whereby a predetermined amount of chlorpheniramine maleate charged to the process is maintained in the...
|
|
|
5622716 |
Process for preparing a retard product containing diltiazem for a single daily administration
This invention is directed towards pellets and a process for manufacturing pellets of diltiazem HCl having a dissolution kinetic independent from pH.
|
|
|
5607695 |
Process for the manufacture of porous cellulose matrices
A process for the manufacture of porous cellulose particles, which have regular shape, and a capacity of sorbing 1.5-9 times of their own weight of water, a tap bulk density of less than 0.85 g/ml...
|
|
|
5607697 |
Taste masking microparticles for oral dosage forms
The present invention relates to a solid dosage form including a new type of taste masking microparticle having an adsorbate of, for example, mannitol, in the core thereof.
|
|
|
5595762 |
Stabilized pulverulent active agents, compositions containing them, process for obtaining them and their applications
Stabilized pulverulent active agents, compositions containing them and also process for obtaining them; such stabilized active agents enable dry and stable pharmaceutical, dietary, nutritional or...
|
|
|
5593690 |
Sustained release preparations
There is provided a matrix preparation produced by dispersing a pharmaceutically active ingredient into a matrix which is solid at ambient temperature and comprised of a fatty acid ester of a...
|
|
|
5589191 |
Slow-release sodium valproate tablets
A slow, release sodium valproate tablet with a coating layer, obtained by coating a core containing sodium valproate with a coating agent comprising ethyl cellulose having silicic acid anhydride...
|
|
|
5580580 |
Formulations and their use in the treatment of neurological diseases
Pharmaceutical formulations comprise a mono- or di-aminopyridine active agent for administration on a once- or twice-daily basis for use in the treatment of neurological diseases, in particular...
|
|
|
5571536 |
Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
Nanoparticulate crystalline drug substances formulated in an aqueos phase emulsified in oil, are able to be made at less than 1000 nm size and provide increased bioavailability and lymphatic uptake...
|
|
|
5571532 |
Pharmaceutical preparation for supplying fluoride ions
Pharmaceutical preparation in tablet form for supplying fluoride ions for the treatment and prevention of losses of bone substance, including osteoporosis and alveolar bond damage, with a content...
|
|
|
5569468 |
Vaccine delivery system for immunization, using biodegradable polymer microspheres
A controlled release oral formulation, for human vaccines, are formed in microspherical form. The vaccine is suspended in a polymer matrix. The polymer matrix is formed from at least two highly...
|
|
|
5565188 |
Polyalkylene block copolymers as surface modifiers for nanoparticles
There is disclosed a composition containing nanoparticles having a surface modifier wherein the surface modifier is a block copolymer containing one or more polyoxyethylene blocks and one or more...
|
|
|
5560928 |
Nutritional and/or dietary composition and method of using the same
A composition and method of using the same which provides in as little as a single dose covering a 24 hour period a nutritional and/or dietary supplement which provides administration of water...
|
|
|
5552160 |
Surface modified NSAID nanoparticles
Dispersible particles consisting essentially of a crystalline NSAID having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size...
|
|
|
5545410 |
Method of controlling the release of carbohydrates by encapsulation and composition therefor
A composition of carbohydrates having an edible coating is disclosed, whereby the coated carbohydrate, when orally ingested, causes a time delay release of the carbohydrate into the digestive...
|
|
|
5536507 |
Colonic drug delivery system
A three component pharmaceutical formulation of one or more pharmacologically active substances such that greater than 80% of the pharmacologically active substance will be released in the large...
|
|
|
5510119 |
Controlled release therapeutic system for liquid pharmaceutical formulations
Disclosed is a controlled release pharmaceutical dosage form, including: (a) microgranules of a pharmaceutical and an excipient; (b) a plurality of polymeric lipidic and wax-like coatings applied...
|
|
|
5508042 |
Controlled release oxycodone compositions
A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation...
|
|
|
5508044 |
Diltiazem pharmaceutical spheroid formulation
A solid oral dosage form comprising diltiazem (or a pharmaceutically acceptable salt thereof) in controlled release form and hydrochlorothiazide in immediate release form. Preferably, the...
|
|
|
5505967 |
Microparticulate pharmaceutical delivery system
A pharmaceutical composition comprising a shaped enteric material having distributed therethrough preferably substantially uniformly, pharmaceutical loaded particles, said particles having a size...
|
|
|
5501863 |
Contrast media synthesized from polyaldehydes
Microparticles comprising biodegradable polymers, characterized in that they are synthesized from polymerizable aldehydes, which optionally contain additives and/or crosslinkers capable of...
|
|
|
5496561 |
Controlled release-initiation and controlled release-rate pharmaceutical composition
A controlled release-initiation and controlled release-rate pharmaceutical composition in which a drug-containing composition is coated with a membrane layer comprising a water insoluble high...
|
|
|
5494681 |
Tastemasked pharmaceutical materials
A substantially tasteless pharmaceutical delivery system, which comprises a) an active material; and b) a spatially oriented matrix comprising (i) a wax core material having a melting point within...
|
|
|
5494683 |
Surface modified anticancer nanoparticles
Dispersible particles consisting essentially of a crystalline anticancer agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average...
|
|
|
5492700 |
Process and composition for the development of controlled release gemfibrozil dosage form
Gemfibrozil formulations prepared from a single granulation of gemfibrozil and a release-control agent are disclosed. The release-control agent is present in an amount sufficient to provide both...
|
|
|
5480654 |
Prolonged release dosage form of drug and method for producing the same
A prolonged release dosage form of drug made by coating a surface of an ungranulated medicinal particle with a water-insoluble material which is physiologically acceptable and does not dissolve in...
|
|
|
5464632 |
Rapidly disintegratable multiparticular tablet
Rapidly disintegratable multiparticulate tablet the excipient mixture of which is suitable for imparting a disintegration rate such that the tablet disintegrates in the mouth in an extremely short...
|
|
|
5458872 |
Method for the protection of dihydroxyacetone, a dihydroxyacetone protected by this method, and a cosmetic product containing such a protected dihydroxyacetone
A method for protecting and stabilizing dihydroxyacetone (DHA) is described. The method is characterized in that at least a part of the dihydroxyacetone is enclosed in dimer form in a watertight...
|